TY - JOUR
T1 - Competitive allele-specific short oligonucleotide hybridization (CASSOH) with enzyme-linked immunosorbent assay (ELISA) for the detection of pharmacogenetic single nucleotide polymorphisms (SNPs)
AU - Hiratsuka, Masahiro
AU - Ebisawa, Aiko
AU - Sakuyama, Kanako
AU - Matsubara, Yoichi
AU - Kure, Shigeo
AU - Soya, Yoshihiro
AU - Konno, Yumiko
AU - Sasaki, Takamitsu
AU - Kishiba, Akiko
AU - Mizugaki, Michinao
N1 - Funding Information:
This work was supported by a Grant-in-Aid from the Suzuken Memorial Foundation and partly by a Grant-in-Aid for Research on Advanced Medical Technology from the Ministry of Health, Labor and Welfare of Japan and in part by High-Tech Research Center Program from the Ministry of Education, Culture, Sports, Science, and Technology of Japan.
PY - 2006/6/30
Y1 - 2006/6/30
N2 - Individualization of drug therapy through genetic testing would maximize the effectiveness of medication and minimize its risks. Recent progress in genetic testing technologies has been remarkable, and they have been applied for the analysis of genetic polymorphisms that regulate drug responses. Clinical application of genetic information to individual health care requires simple and rapid identification of nucleotide changes in clinical settings. We previously reported a novel DNA diagnostic method for detecting single nucleotide polymorphisms (SNPs) using competitive allele-specific short oligonucleotide hybridization (CASSOH) with an immunochromatographic strip. We have developed the method further in order to incorporate an enzyme-linked immunosorbent assay (ELISA) into the final detection step; this enables multiple SNP detection. Special ELISA chips have been fabricated so that disposal of buffer waste is not required and handling procedures are minimized. This method (CASSOH-ELISA) has been successfully applied for the detection of clinically important SNPs in drug metabolism, such as N-acetyltransferase 2, NAT2*6 (590G>A) and NAT*7 (857G>A), and mitochondrial DNA (1555A>G). It would also facilitate point-of-care genetic testing for potentially diverse clinical applications.
AB - Individualization of drug therapy through genetic testing would maximize the effectiveness of medication and minimize its risks. Recent progress in genetic testing technologies has been remarkable, and they have been applied for the analysis of genetic polymorphisms that regulate drug responses. Clinical application of genetic information to individual health care requires simple and rapid identification of nucleotide changes in clinical settings. We previously reported a novel DNA diagnostic method for detecting single nucleotide polymorphisms (SNPs) using competitive allele-specific short oligonucleotide hybridization (CASSOH) with an immunochromatographic strip. We have developed the method further in order to incorporate an enzyme-linked immunosorbent assay (ELISA) into the final detection step; this enables multiple SNP detection. Special ELISA chips have been fabricated so that disposal of buffer waste is not required and handling procedures are minimized. This method (CASSOH-ELISA) has been successfully applied for the detection of clinically important SNPs in drug metabolism, such as N-acetyltransferase 2, NAT2*6 (590G>A) and NAT*7 (857G>A), and mitochondrial DNA (1555A>G). It would also facilitate point-of-care genetic testing for potentially diverse clinical applications.
KW - Genotyping
KW - Pharmacogenetics
KW - Single nucleotide polymorphism
UR - http://www.scopus.com/inward/record.url?scp=33646177887&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33646177887&partnerID=8YFLogxK
U2 - 10.1016/j.jbbm.2006.01.005
DO - 10.1016/j.jbbm.2006.01.005
M3 - Article
C2 - 16546261
AN - SCOPUS:33646177887
SN - 0165-022X
VL - 67
SP - 87
EP - 94
JO - Journal of Biochemical and Biophysical Methods
JF - Journal of Biochemical and Biophysical Methods
IS - 2-3
ER -